#1 Clinical Trials Search in Europe

Enoxaparin Sodium

This article explores the use of Enoxaparin Sodium, a widely used low-molecular-weight heparin, in various clinical trials. These studies aim to evaluate the drug’s efficacy, safety, and bioequivalence compared to other formulations or similar medications. Enoxaparin Sodium is commonly used for preventing and treating blood clots, making it a crucial medication in managing conditions like deep vein thrombosis and pulmonary embolism.

Table of Contents

What is Enoxaparin Sodium?

Enoxaparin Sodium is a medication that belongs to a class of drugs called low molecular weight heparins (LMWHs). It is commonly known by brand names such as Clexane, Lovenox, or Inhixa[1]. Enoxaparin is derived from the intestinal mucosa of pigs and is used as an anticoagulant, which means it helps prevent blood clots from forming[2].

How Does Enoxaparin Work?

Enoxaparin works by enhancing the effect of a natural substance in your body called antithrombin III. This substance helps to prevent harmful blood clots by blocking clotting proteins in your blood. Specifically, enoxaparin inhibits two important factors in the blood clotting process: factor Xa and factor IIa (also known as thrombin)[2]. By doing this, enoxaparin helps to thin your blood and reduce the risk of dangerous clots forming in your veins or arteries.

Medical Uses of Enoxaparin

Enoxaparin is used to treat and prevent various conditions related to blood clots. Some of its main uses include:

  • Prevention of Deep Vein Thrombosis (DVT): This is a condition where blood clots form in the deep veins, usually in the legs. Enoxaparin is often used to prevent DVT in patients undergoing orthopedic surgeries such as hip or knee replacement[3].
  • Treatment of Venous Thromboembolism (VTE): This includes both DVT and pulmonary embolism (PE), which is when a blood clot travels to the lungs[4].
  • Prevention of blood clots in patients with acute illnesses: This includes patients who are bedridden due to heart failure, severe respiratory diseases, or other medical conditions that limit mobility[1].
  • Treatment of certain types of heart attacks: Specifically, it’s used in the treatment of ST-segment elevation myocardial infarction (STEMI), a severe type of heart attack[5].

How is Enoxaparin Administered?

Enoxaparin is typically administered as a subcutaneous injection, which means it’s injected just under the skin, usually in the abdomen area. It comes in pre-filled syringes, making it easier for patients to self-administer if necessary[2]. Your healthcare provider will show you or your caregiver how to properly give the injection if you need to do it at home.

Dosage Information

The dosage of enoxaparin can vary depending on the condition being treated, the patient’s weight, and other factors. Some common dosages include:

  • For preventing DVT after surgery: 40 mg once daily, starting 12 hours before surgery[6].
  • For treating DVT or PE: 1 mg per kg of body weight every 12 hours, or 1.5 mg per kg once daily[1].
  • For preventing blood clots in acutely ill patients: 40 mg once daily for 6 to 14 days[1].

Always follow your doctor’s instructions regarding dosage and administration schedule.

Potential Side Effects

Like all medications, enoxaparin can cause side effects. Some of the most common include:

  • Bleeding: This can range from minor bleeding (such as nosebleeds or bleeding gums) to more serious internal bleeding[3].
  • Bruising or pain at the injection site[2].
  • Allergic reactions: These can include skin rashes or more severe symptoms[3].
  • Low platelet count (thrombocytopenia): This is a rare but serious side effect that requires immediate medical attention[3].

If you experience any unusual symptoms while taking enoxaparin, contact your healthcare provider immediately.

Current Research and Studies

Enoxaparin continues to be the subject of ongoing research to explore its effectiveness in various conditions:

  • COVID-19 Treatment: Studies are investigating the use of enoxaparin in treating severe COVID-19 cases with coagulation disorders[1].
  • Pediatric Use: Research is being conducted to determine safe and effective dosing of enoxaparin in children and neonates with thrombosis[7].
  • Bioequivalence Studies: Researchers are comparing the effectiveness of generic versions of enoxaparin to the brand-name versions to ensure they work similarly in the body[2].

These ongoing studies aim to expand our understanding of enoxaparin and potentially broaden its medical applications.

Aspect Details
Primary Uses Prevention and treatment of blood clots, including deep vein thrombosis and pulmonary embolism
Administration Subcutaneous injection, with doses ranging from 30 mg to 100 mg
Key Outcome Measures Anti-Factor Xa activity, Anti-Factor IIa activity, Tissue Factor Pathway Inhibitor levels, incidence of thrombotic events
Safety Considerations Bleeding risk, injection site reactions, potential for heparin-induced thrombocytopenia
Comparison Methods Bioequivalence studies measuring pharmacodynamic parameters like Amax and AUEC
Clinical Trial Designs Randomized, cross-over studies comparing different formulations or comparing to standard treatments
Patient Populations Healthy volunteers for bioequivalence studies; patients with or at risk of thrombotic events for efficacy studies

FAQ

  • What is Enoxaparin Sodium used for? Enoxaparin Sodium is primarily used to prevent and treat blood clots. It's commonly prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and for preventing venous thromboembolism in patients undergoing certain surgeries or those at high risk of developing blood clots.
  • How is Enoxaparin Sodium administered? Enoxaparin Sodium is typically administered as a subcutaneous (under the skin) injection. The dosage and frequency can vary depending on the specific condition being treated and the patient's individual needs. In clinical trials, doses ranging from 30 mg to 100 mg have been studied.
  • What are the main outcomes measured in Enoxaparin Sodium clinical trials? Clinical trials for Enoxaparin Sodium often measure outcomes such as anti-Factor Xa activity, anti-Factor IIa activity, tissue factor pathway inhibitor (TFPI) levels, and the incidence of thrombotic events. Safety outcomes typically include the frequency of bleeding events and other adverse reactions.
  • How do researchers compare different formulations of Enoxaparin Sodium? Researchers often use bioequivalence studies to compare different formulations of Enoxaparin Sodium. These studies measure pharmacodynamic parameters like maximum activity (Amax) and area under the effect curve (AUEC) for anti-FXa and anti-FIIa activities. The goal is to demonstrate that the new formulation is equivalent to the reference product in terms of efficacy and safety.
  • Are there any potential side effects of Enoxaparin Sodium? Like all medications, Enoxaparin Sodium can have side effects. The most common concern is bleeding, which can range from minor to major. Other potential side effects include injection site reactions, elevated liver enzymes, and rarely, a condition called heparin-induced thrombocytopenia. Clinical trials closely monitor these safety outcomes to ensure the benefits of the medication outweigh the risks.

Ongoing Clinical Trials on Enoxaparin Sodium

  • Comparison of REGN7508 versus apixaban and enoxaparin to prevent blood clots in adults after knee replacement surgery

    Recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Hungary Latvia Lithuania Poland Romania

  • Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

    Recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Hungary Latvia Lithuania Poland

  • Evaluation of Enoxaparin for Prevention of Localized Intravascular Coagulopathy in Children with Slow-Flow Vascular Malformations Undergoing Interventional Procedures

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Finland Iceland The Netherlands Sweden

  • Study on Dalteparin Sodium and Enoxaparin Sodium for Preventing Blood Clots in Patients Undergoing Liver Surgery

    Recruiting

    1 1 1 1
    Investigated drugs:
    Norway

  • Study on Anticoagulation Strategies with Heparin, Enoxaparin, and Argatroban for Patients with Respiratory or Circulatory Failure on ECMO Support

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Preventing Blood Clots in Pancreatic Cancer Patients Using Tinzaparin Sodium and Enoxaparin Sodium During Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

    Recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study of Enoxaparin Treatment in Pregnant Women with Early Fetal Growth Restriction

    Recruiting

    1 1 1 1
    Investigated drugs:
    Portugal

  • Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Croatia France Germany Hungary +5

Glossary

  • Anti-Factor Xa (anti-FXa) activity: A measure of the blood's ability to inhibit clotting factor Xa, which is used to assess the anticoagulant effect of Enoxaparin Sodium.
  • Anti-Factor IIa (anti-FIIa) activity: A measure of the blood's ability to inhibit clotting factor IIa (thrombin), another indicator of Enoxaparin Sodium's anticoagulant effect.
  • Area Under the Effect Curve (AUEC): A pharmacodynamic parameter that represents the total effect of a drug over time, used to compare different formulations of Enoxaparin Sodium.
  • Bioequivalence: The property of two drug products having similar bioavailability and producing the same effect at the site of physiological activity.
  • Deep Vein Thrombosis (DVT): A blood clot that forms in a deep vein, usually in the leg, which can be prevented or treated with Enoxaparin Sodium.
  • Enoxaparin Sodium: A low-molecular-weight heparin used to prevent and treat blood clots by inhibiting clotting factors in the blood.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pulmonary Embolism (PE): A blockage in one of the pulmonary arteries in the lungs, often caused by blood clots that travel from the legs or other parts of the body.
  • Subcutaneous (SC) injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Tissue Factor Pathway Inhibitor (TFPI): A protein that helps regulate blood clotting and is released by Enoxaparin, contributing to its anticoagulant effect.
  • Venous Thromboembolism (VTE): A condition that includes both deep vein thrombosis and pulmonary embolism, which Enoxaparin Sodium is used to prevent and treat.

References

  1. https://clinicaltrials.gov/study/NCT04408235
  2. https://clinicaltrials.gov/study/NCT05265676
  3. https://clinicaltrials.gov/study/NCT02368314
  4. https://clinicaltrials.gov/study/NCT01308528
  5. https://clinicaltrials.gov/study/NCT00718471
  6. https://clinicaltrials.gov/study/NCT02128178
  7. https://clinicaltrials.gov/study/NCT02486666